Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

Benzinga Earnings

Aug 12

Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.

The company posted quarterly losses of 82 cents per share which beat the analyst consensus estimate of losses of 84 cents per share. This represents a 64% decrease over losses of 50 cents per share in the year-ago period.

Bicara Therapeutics shares dipped 14.3% to close at $23.76 on Tuesday.

These analysts made changes to their price targets on Bicara Therapeutics following earnings announcement.

BTIG analyst Jeet Mukherjee maintained the stock with a Buy and raised the price target from $28 to $39.
Wells Fargo analyst Eva Fortea Verdejo maintained the stock with an Equal-Weight rating and raised the price target from $16 to $23.

Considering buying BCAX stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2658797794"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2658797794\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2658797794?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-12 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658797794","market":"us","top_or_hot":-1,"title":"Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results","media":"Benzinga Earnings","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/BCAX\">Bicara Therapeutics</a> Inc</strong> (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.</p>\n<p>The company posted quarterly losses of 82 cents per share which beat the analyst consensus estimate of losses of 84 cents per share. This represents a 64% decrease over losses of 50 cents per share in the year-ago period.</p>\n<p>Bicara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares dipped 14.3% to close at $23.76 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Bicara Therapeutics following earnings announcement.</p>\n<ul>\n<li>BTIG analyst Jeet Mukherjee maintained the stock with a Buy and raised the price target from $28 to $39.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Eva Fortea Verdejo maintained the stock with an Equal-Weight rating and raised the price target from $16 to $23.</li>\n</ul>\n<p><strong>Considering buying BCAX stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"299\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/12083323/image-330-1024x299.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/12083323/image-330-1024x299.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/12083323/image-330-300x88.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/12083323/image-330-768x224.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/12083323/image-330.png 1172w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBicara Therapeutics Analysts Raise Their Forecasts After Q2 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-08-12 20:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/BCAX\">Bicara Therapeutics</a> Inc</strong> (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.</p>\n<p>The company posted quarterly losses of 82 cents per share which beat the analyst consensus estimate of losses of 84 cents per share. This represents a 64% decrease over losses of 50 cents per share in the year-ago period.</p>\n<p>Bicara <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares dipped 14.3% to close at $23.76 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Bicara Therapeutics following earnings announcement.</p>\n<ul>\n<li>BTIG analyst Jeet Mukherjee maintained the stock with a Buy and raised the price target from $28 to $39.</li>\n<li><a href=\"https://laohu8.com/S/EOD\">Wells Fargo</a> analyst Eva Fortea Verdejo maintained the stock with an Equal-Weight rating and raised the price target from $16 to $23.</li>\n</ul>\n<p><strong>Considering buying BCAX stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"299\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/12083323/image-330-1024x299.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/12083323/image-330-1024x299.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/12083323/image-330-300x88.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/12083323/image-330-768x224.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/08/12083323/image-330.png 1172w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61139731/bicara-therapeutics-analysts-raise-their-forecasts-after-q2-results","article_id":"2658797794","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2658797794","pubTimestamp":1786538072,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targets, but shares dipped 14.3% to $23.76. #BCAX #earnings","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BCAX":"Bicara Therapeutics"},"translate_title":"Bicara Therapeutics 分析师在第二季度业绩公布后上调预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCAX":1.5},"content_text":"Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.\nThe company posted quarterly losses of 82 cents per share which beat the analyst consensus estimate of losses of 84 cents per share. This represents a 64% decrease over losses of 50 cents per share in the year-ago period.\nBicara Therapeutics shares dipped 14.3% to close at $23.76 on Tuesday.\nThese analysts made changes to their price targets on Bicara Therapeutics following earnings announcement.\n\nBTIG analyst Jeet Mukherjee maintained the stock with a Buy and raised the price target from $28 to $39.\nWells Fargo analyst Eva Fortea Verdejo maintained the stock with an Equal-Weight rating and raised the price target from $16 to $23.\n\nConsidering buying BCAX stock? Here’s what analysts think:\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}